Drug selection in early drug development: Screening for acceptable pharmacokinetic properties using combined in vitro and computational approaches

Current Opinion in Drug Discovery and Development

Volumn 2, Issue 1, 1999, Pages 42-48

  Sinko, Patrick J ^a  

^a RUTGERS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DRUG;

AREA UNDER THE CURVE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG DEVELOPMENT; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG EXCRETION; DRUG METABOLISM; DRUG SAFETY; GASTROINTESTINAL ABSORPTION; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; NONHUMAN; ORAL DRUG ADMINISTRATION; PHARMACOGENETICS; PHARMACOKINETICS; PREDICTION; REVIEW;

EID: 0032900661     PISSN: 13676733     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (35)

1. Pharmaceutical News, September 1994.
2. AAPS (American Association of Physicians and Surgeons) Newsletter, 1995.
3. Abelson PH: Improvements in health care [editorial]. Science (1993) 260:11.
4. Prenlis RA, Lis Y, Walker SR: Pharmaceutical innovation by the seven UK-owned pharmaceutical companies (1964-1985). Br J Clin Pharma (1988) 25:387-396.
5. Mattison N, Thomas E, Trimble AG, Wardell WM: The development of self-originated new drugs by Swiss pharmaceutical firms. Regul Toxicol Pharmacol (1984) 4:157-173.
6. Wardell WM, Di Raddo J: The measurement of pharmaceutical innovation. J Clin Pharmacol (1980) 20:1-9.
7. Kennedy T: Managing the drug discovery/development interface. Drug Discovery Today (1997) 2:436-444 (1997).
8. Sietsema WK: The absolute oral bioavailability of selected drugs. Int J Clin Pharmacol Ther Toxicol (1989) 27:179-211.
9. A comprehensive collection of absolute bioavailability results in various species including humans.
10. Watkins PB: The barrier function of CYP3A4 and Pglycoprotein in the small bowel. Adv Drug Del Rev (1997) 27:161-170.
11. This entire issue of Advanced Drug Delivery Reviews is devoted to intestinal/hepatic clearance, including metabolism and efflux.
12. Makhey VD, Quo A, Norn's DA, Hu P, Van J. Sinko PJ: Characterization of the regional intestinal kinetics of drug efflux in rat and human intestine and in Caco-2 cells. Pharm Res (1998) 15:1160-1167.
13. Demonstrates common methods of measuring permeability and interpreting results.
14. Rubas W, Villagran J, Cromwell M, McLecd A, Wassenberg J, Mrsny R: Correlation of solute flux across Caco-2 monolaycrs and colonie tissue In vitro. STP Pharma Sci (1995)5:93-97.
15. Lin JH: Species similarities and differences in pharmacokinetics. Drug Metab Dispos (1995) 23:1008-1021.
16. Lee CP, de Vrueh RLA, Smith PL: Selection of development candidates based on in vitro permeability measurements. Adv Drug Del Rev (1997) 23:47-62.
17. Karali IT: Comparison of the gastrointestinal anatomy, physiology, and biochemistry of humans and commonly used laboratory animals. Biopharm Drug Dispos (1995) 16:351-380.
18. Chiou WL: We may not measure the correct intestinal wall permeability coefficient of drugs: alternative absorptive clearance concept J Pharmacokinet Biopharm (1995) 23:323-331.
19. Lennemas H, Crison JR, Amidon GL: Permeability and clearance views of drug absorption: a commentary. J Pharmacokinet Biopharm (1995) 23:333-343.
20. Chiou WL: Response. J Pharmacokinet Biopharm (1995) 23:344-347.
21. Stewart BH, Chan OH. Jezyk N, Fleisher D: Discrimination between drug candidates using models for evaluation of intestinal absorption. Adv Drug Del Rev (1997) 23:27-45.
22. This issue of Advanced Drug Delivery Reviews focuses on lead candidate selection.
23. Lennemas H: Human intestinal permeability. J Pharm Sci (1998)87:403-410.
24. Knipp GT, Vander Velde DG, Siahaan TJ, Borchardt RT: The effect of beta-turn structure on the passive diffusion of peptides across Caco-2 cell monolayers. Pharm Res (1997) 14:1332-1340.
25. Fogh J, Fogh JM, Orfeo T: One hundred and twenty-seven cultured human tumor cell lines producing tumors in nude mice. J Natl Cancer Inst (1977) 59:221 -226.
26. Délie F, Rubas W: A human colonie cell line sharing similarities with enterocytes as a model to examine oral absorption: Advantages and limitations of the Caco-2 model. Crit Rev Ther Drug Carrier Syst (1997) 14:221 -286.
27. Artursson P, Borchardt RT: Intestinal drug absorption and metabolism in cell cultures: Caco-2 and beyond. Pharm Res (1997) 14:1655-1658.
28. Dressman JB, Amidon GL, Fleisher D: Absorption potential: Estimating the fraction absorbed for orally administered compounds. J Pharm Sci (1985) 74:588-589.
29. Amidon GL, Sinko PJ, Fleisher D: Estimating human oral fraction dose absorbed: A correlation using rat intestinal membrane permeability for passive and carrier mediated compounds. Pharm Res (1988) 5:651 -654.
30. Artursson P, Karlsson J: Correlation between oral drug absorption in humans and apparent drug permeability coefficients in human intestinal epithelial (Caco-2) cells. Biochem Biophys Res Commun (1991 ) 175:880-885.
31. Shore PA, Brodle BB, Hogben CAM: The gastric secretion of drugs: A pH partition hypothesis. J Pharmacol Exp Ther (1957)119:361-369.
32. Grass GM: Simulation models to predict oral drug absorption from in vitro data. Adv Drug Del Rev (1997) 23:199-219.
33. One of the first demonstrations of the use of in vitro parameters to predict pharmacokinetics.
34. Lipinski CA, Lombardo F, Dominy BW, Feeney PJ: Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Del Rev (1997) 23:3-25.
35. A popular method for initial screening of NCEs.